Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ManiMNICF 92 3-Year EPS without NRI Growth Rate is 0.10% as of May. 2026, which is 99% below its 10-year median of 7.70. GuruFocus rates MNICF with a GF Score™ of 92/100 and a GF Value™ of $19.40. The stock has 2 warning signs investors should review. Among 662 Medical Devices & Instruments companies, Mani ranks worse than 61.48% on this metric.
During the past 12 months, Mani's average EPS without NRI Growth Rate was 5.20% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 0.10% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 13.10% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 8.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Mani was 33.80% per year. The lowest was -20.30% per year. And the median was 7.70% per year.
Mani (OTCPK:MNICF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Mani 3-Year EPS without NRI Growth Rate Related Terms
MNICF vs ISRG, BDX, RMD: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Mani's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mani 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Mani's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Mani's 3-Year EPS without NRI Growth Rate falls into.
Mani 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 0.10% mean?
Mani (MNICF) has a 3-Year EPS without NRI Growth Rate of 0.10% as of May. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Mani and its competitors. This is 99% below median its historical median of 7.70. According to the industry distribution chart, Mani ranks #407 out of 662 companies in the Medical Devices & Instruments industry, placing it in the top 61.5%.
Is Mani's 3-Year EPS without NRI Growth Rate too high?
Mani's current 3-Year EPS without NRI Growth Rate of 0.10% is 99% below median its 10-year median of 7.70. The Medical Devices & Instruments industry median 3-Year EPS without NRI Growth Rate is 8.05. Mani's value of 0.10% is 98.8% below this industry median. Based on the distribution chart, Mani ranks #407 out of 662 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Mani has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does Mani's 3-Year EPS without NRI Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Mani ranks #407 out of 662 companies for 3-Year EPS without NRI Growth Rate. This places Mani in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 8.05. Mani's value of 0.10% is 98.8% below this benchmark. While the company's 10-year median is 7.70 vs. the industry median of 8.05, Mani has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 8.05, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mani's current 3-Year EPS without NRI Growth Rate of 0.10% is 98.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Mani and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 8.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mani's current 3-Year EPS without NRI Growth Rate is 0.10%, which is 99% below median its own 10-year median of 7.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mani stock overvalued right now?
Mani (MNICF) has a current 3-Year EPS without NRI Growth Rate of 0.10%. The stock's GF Value™ is $19.40, compared to a current price of $12.82 — trading 33.9% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 0.10%, which is 99% below median its 10-year median of 7.70 and 98.8% below the Medical Devices & Instruments industry median of 8.05. Mani's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Mani (MNICF), the current 3-Year EPS without NRI Growth Rate is 0.10% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mani (MNICF) Overvalued in 2026?
Based on GuruFocus' analysis, Mani stock appears to be undervalued.
The current stock price of $12.82 is trading 33.9% below its estimated GF Value™ of $19.40.
Key valuation signals for MNICF:
3-Year EPS without NRI Growth Rate: 0.10% (99% below median its 10-year median of 7.70)
GF Value™: $19.40 vs. price of $12.82 (33.9% below fair value)
Industry Position: 98.8% below the Medical Devices & Instruments median (#407 of 662)
No single metric tells the full story. See the MNICF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mani Inc manufactures medical devices and dental instruments. It sells products in four categories: surgical instruments, ophthalmic instruments, suture needles, and dental instruments. Mani's surgical products include instruments such as staplers, vessel knives, and bone saws. Its ophthalmic instruments include a range of knives used during eye surgery and ophthalmic sutures. Mani's suture needles business includes a variety of taper point and cutting eyeless needles, which require suture attachment and sterilization by the customer, as well as stainless-steel eyed needles. The firm's dental instruments include endodontic instruments and accessories, root canal equipment, and finishing and polishing instruments.
92GF Score
Get the complete analysis for MNICF
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MNICF has been successfully added to your 
